Validation of the Functional Assessment of Cancer Therapy - Lymphoma (FACT-LYM) in Patients with Relapsed/Refractory Mantle Cell Lymphoma.

被引：0
|
作者：
Carter, Gebra Cuyun [1 ]
Liepa, Astra M. [1 ]
Zimmermann, Anna Hayden [2 ]
Morschhauser, Franck [3 ]
机构：
[1] Eli Lilly & Co, Global Hlth Outcomes, Indianapolis, IN 46285 USA
[2] Eli Lilly & Co, Stat, Indianapolis, IN 46285 USA
[3] Ctr Hosp Univ, Lille, France
来源：
BLOOD | 2008年 / 112卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：828 / 828
页数：1
相关论文
共 50 条
  • [21] Sequencing Therapies in Relapsed/Refractory Mantle Cell Lymphoma
    Portell, Craig A.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S129 - S130
  • [22] Gemcitabine plus rituximab therapy of patients with relapsed and refractory classical Hodgkin lymphoma.
    Younes, A
    Fayad, L
    Pro, B
    Goy, A
    Romaguera, JE
    Hagemeister, FB
    McLaughlin, P
    BLOOD, 2005, 106 (11) : 431A - 431A
  • [23] CAR T-cell therapy for relapsed or refractory mantle-cell lymphoma
    Stirrups, Robert
    LANCET ONCOLOGY, 2020, 21 (05): : E239 - E239
  • [24] Gemcitabine with dexamethasone plus /-cisplatin in patients with relapsing/refractory mantle cell lymphoma.
    Morschhauser, F
    Marit, G
    Jourdan, E
    Solal-Celigny, P
    Fitoussi, O
    Wetterwald, M
    Rose, C
    Sebban, C
    Bouabdallah, R
    Kayitalire, L
    Dumontet, C
    BLOOD, 2002, 100 (11) : 292B - 293B
  • [25] Bortezomib in combination with fludarabine plus cyclophosphamide for patients with relapsed or refractory mantle-cell lymphoma: results of the LYM-4003 study
    Wang, Xiao-Xiao
    Gao, Yan
    Jin, Jie
    Cao, Jun-Ning
    Feng, Ji-Feng
    Wang, Hua-Qing
    Zhang, Hui-Lai
    Cai, Qing-Qing
    Li, Zhi-Ming
    Jiang, Wen-Qi
    Huang, Hui-Qiang
    ANNALS OF HEMATOLOGY, 2021, 100 (12) : 2961 - 2968
  • [26] Bortezomib in combination with fludarabine plus cyclophosphamide for patients with relapsed or refractory mantle-cell lymphoma: results of the LYM-4003 study
    Xiao-Xiao Wang
    Yan Gao
    Jie Jin
    Jun-Ning Cao
    Ji-Feng Feng
    Hua-Qing Wang
    Hui-Lai Zhang
    Qing-Qing Cai
    Zhi-Ming Li
    Wen-Qi Jiang
    Hui-Qiang Huang
    Annals of Hematology, 2021, 100 : 2961 - 2968
  • [27] Phase I/II clinical trial of ibrutinib and buparlisib in relapsed/refractory diffuse large B-cell lymphoma, mantle cell lymphoma, and follicular lymphoma.
    Batlevi, Connie Lee
    De Frank, Stephanie
    Stewart, Caitlin
    Hamlin, Paul A.
    Matasar, Matthew J.
    Gerecitano, John F.
    Moskowitz, Alison J.
    Hamilton, Audrey M.
    Zelenetz, Andrew David
    Drullinsky, Pamela
    Straus, David J.
    Kumar, Anita
    Moskowitz, Craig H.
    Dicostanzo, Joanna
    Callan, Devin
    Tsui, Dana
    Rademaker, Jurgen
    Schoder, Heiko
    Ni, Ai
    Younes, Anas
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [28] TREATMENT OF RELAPSING OR REFRACTORY MANTLE CELL LYMPHOMA. UNICENTRIC STUDY
    Marc, Sorigue
    Juan-Manuel, Sancho
    Lluis, Virgili
    Miriam, Moreno
    Cristina, Motllo
    Gustavo, Tapia
    Susanna, Gassiot
    Alberto, Pineda
    Jose-Luis, Mate
    Laura, Abril
    Monica, Linares
    Clara, Maluquer
    Edurne, Sarrate
    Ana, Triguero
    Neus, Ruiz-Xiville
    Anna, Torrent
    Susana, Vives
    Christelle, Ferra
    Blanca, Xicoy
    Montserrat, Batlle
    Gladys, Ibarra
    Immaculada, Portal
    Jose-Tomas, Navarro
    Evarist, Feliu
    Josep-Maria, Ribera
    HAEMATOLOGICA, 2016, 101 : 207 - 208
  • [29] A Phase II Study of Temsirolimus (CCI-779) in Combination with Rituximab in Patients with Relapsed or Refractory Mantle Cell Lymphoma.
    Ansell, Stephen M.
    Tang, Hui
    Kurtin, Paul
    Koenig, Patricia
    Inwards, David J.
    Shah, Keith
    Witzig, Thomas E.
    BLOOD, 2009, 114 (22) : 664 - 665
  • [30] Clinical Efficacy and Management of Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Lymphoma
    Coiffier, Bertrand
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2013, 13 (04): : 351 - 359
12345